XM no presta servicios a los residentes de Estados Unidos de América.
A
A

Abbott


Noticias

Abbott Advances Pulsed Field Ablation Clinical Studies

BRIEF-Abbott Advances Pulsed Field Ablation Clinical Studies Oct 10 (Reuters) - Abbott Laboratories ABT.N : ABBOTT ADVANCES PULSED FIELD ABLATION CLINICAL STUDIES AND LAUNCHES NEW TECHNOLOGY TO SUPPORT ADVANCED CARDIAC MAPPING ABBOTT: GLOBAL FOCALFLEX TRIAL NOW UNDERWAY FOR ABBOTT'S TACTIFLEX™ DUO ABLATION CATHETER, SENSOR ENABLED™ ABBOTT: ADVISOR™ HD GRID X MAPPING CATHETER, SENSOR ENABLED™, RECEIVES U.S.
A

U.S. Abbott, Gilead, Roku

U.S. RESEARCH ROUNDUP-Abbott, Gilead, Roku Oct 10 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Abbott, Gilead and Roku, on Thursday. HIGHLIGHTS * Abbott ABT.N : JP Morgan raises target price to $135 from $125 * AIG AIG.N : JP Morgan raises to overweight from neutral * Gilead GILD.O : Raymond James raises target price to $95 from $94 * Lendingclub Corp LC.N : KBW raises to outperform from market perform * Roku Inc R
A
C
G
P
C
I
S
A
G
H
P
U

Medical device makers need to 'beat or raise' for stocks to move higher, RBC says

BUZZ-Medical device makers need to 'beat or raise' for stocks to move higher, RBC says ** Analysts at RBC Capital Markets expect procedures to remain strong for remainder of the year, but see downturn in elective procedures in Q3 due to vacation schedules ** Investor sentiment will continue to play key role in how stocks respond given the high-bar,
A

WHO approves first mpox diagnostic test for emergency use

UPDATE 4-WHO approves first mpox diagnostic test for emergency use Updates Oct. 3 story to add company statement in paragraph 4 Oct 3 (Reuters) - The World Health Organization authorized Abbott Laboratories' ABT.N mpox diagnostic test for emergency use on Thursday, the first such approval in the agency's effort to bolster testing capabilities in countries facing outbreaks of the disease.
A
R
L

Jury urged to hold formula makers responsible for premature baby's illness

UPDATE 1-Jury urged to hold formula makers responsible for premature baby's illness Adds material from Abbott, Mead Johnson opening statements By Brendan Pierson Oct 2 (Reuters) - A lawyer for a Missouri mother on Wednesday urged jurors to hold Abbott ABT.N , Reckitt's RKT.L Mead Johnson unit and St. Louis Children's Hospital responsible for a severe intestinal illness that she says her prematurely born son developed after the hospital fed him the companies' formulas.
A

Jury urged to hold formula makers responsible for premature baby's illness

Jury urged to hold formula makers responsible for premature baby's illness By Brendan Pierson Oct 2 (Reuters) - A lawyer for a Missouri mother on Wednesday urged jurors to hold Abbott ABT.N , Reckitt's RKT.L Mead Johnson unit and St. Louis Children's Hospital responsible for a severe intestinal illness that she says her prematurely born son developed after the hospital fed him the companies' formulas.
A

U.S. STOCKS Dine Brands, Pinterest, Nike

BUZZ-U.S. STOCKS ON THE MOVE-Dine Brands, Pinterest, Nike Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes took a beating on Tuesday as reports of escalating tensions in the Middle East made investors sell riskier assets, with the benchmark S&P 500 hitting its lowest in over a week.
A
A
C
L
N
P
S
L
U
U
L
A
C
J
M

Uptake of Dexcom's OTC glucose monitor Stelo outpaces Abbott's Lingo, Citi says

BUZZ-Uptake of Dexcom's OTC glucose monitor Stelo outpaces Abbott's Lingo, Citi says ** Brokerage Citi says early uptake of Dexcom's DXCM.O over-the-counter continuous glucose monitor Stelo is ahead of Abbott's ABT.N Lingo ** Stelo is gaining traction benefitting from an earlier launch compared to Lingo - Citi ** Adds app data points to a recovery for Dexcom, after the glucose monitor maker slashed its annual revenue forecast ** Brokerage says downloads of apps for Dexcom's continuous glucose mo
A

UK's Reckitt falls after court trial over premature baby formula begins

BUZZ-UK's Reckitt falls after court trial over premature baby formula begins ** Shares of Enfamil formula maker Reckitt RKT.L down 1.15% at 4,524p ** Co's unit Mead Johnson, along with US-based Abbott ABT.N , is facing a trial over its premature baby formula causing a severe intestinal illness ** Plaintiffs argue companies failed to warn about the
A

UK Stocks-Factors to watch on Oct 1

UPDATE 1-UK Stocks-Factors to watch on Oct 1 Adds new items, updates futures Oct 1 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher, with futures FFIc1 up 0 .4%. * HALEON: Pfizer PFE.N offloaded shares worth roughly $3.26 billion in Haleon HLN.L at 380 pence apiece, cutting its stake to 15% in the world's largest standalone consumer healthcare firm, a bookrunner said.
A
G
P
R

UK Stocks-Factors to watch on Oct 1

UK Stocks-Factors to watch on Oct 1 Oct 1 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher, with futures FFIc1 up 0.34% * HALEON: Pfizer's PFE.N stake sale in British consumer healthcare company Haleon HLN.L has been upsized by 100 million shares to 640 million shares worth about $3.25 billion with strong demand from investors, a bookrunner familiar with the offering said on Monday.
A
P

Abbott, Reckitt face trial over premature baby formula amid alarm from doctors

CORRECTED-Abbott, Reckitt face trial over premature baby formula amid alarm from doctors Corrects title of Jonathan Davis in paragraph 9, to Chief of Newborn Medicine at Tufts Medical Center Doctors fear losing access to essential formulas for premature babies Plaintiffs argue companies failed to warn about NEC risk from cow's milk-based formula By Brendan Pierson Sept 30 (Reuters) - A Missouri mother and her lawyers this week will aim to convince a jury that Abbott ABT.N , Reckitt's RKT.L Mead
A

Indian shares set to open higher on US rate-cut euphoria

INDIA STOCKS-Indian shares set to open higher on US rate-cut euphoria BENGALURU, Sept 20 (Reuters) - Indian shares are set to open higher on Friday, as an outsized interest rate reduction by the U.S. Federal Reserve and the anticipation of a soft landing for the world's largest economy boosted risk appetite across global markets. The GIFT Nifty GIFc1 was at 25,523 points, as of 07:55 a.m.
A
U

U.S. STOCKS Children's Place, US energy sector, retailers

BUZZ-U.S. STOCKS ON THE MOVE-Children's Place, US energy sector, retailers Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes soared on Thursday with the S&P 500 and the Dow hitting intraday record highs after the Federal Reserve kicked off its monetary easing cycle with half-a-percentage point reduction and forecast more interest rate cuts were on the hor
A
A
C
C
I
J
L
M
N
T
A
U
F
R
U
U
S
D

Abbott Declares Qtrly Common Dividend Of 55 Cents/Shr

BRIEF-Abbott Declares Qtrly Common Dividend Of 55 Cents/Shr Sept 19 (Reuters) - Abbott Laboratories ABT.N : ABBOTT - DECLARED A QUARTERLY COMMON DIVIDEND OF 55 CENTS PER SHARE ABBOTT DECLARES 403RD CONSECUTIVE QUARTERLY DIVIDEND Source text for Eikon: ID:nPnbB2dYca Further company coverage: ABT.N
A

Piper Sandler initiates coverage on Abbott with 'overweight' rating

BUZZ-Piper Sandler initiates coverage on Abbott with 'overweight' rating ** Brokerage Piper Sandler initiates coverage on Abbott Laboratories ABT.N with overweight rating and PT of $131 ** Says while execution has been strong, ABT shares have underperformed YTD due to the ongoing litigation related to necrotizing enterocolitis (NEC) in premature babies, which has been an overhang ** Brokerage believes the potential damages related to the lawsuit are already priced in ** Considers ABT to be "one
A

U.S. Athira Pharma, Lowe's Companies, P&G

U.S. RESEARCH ROUNDUP-Athira Pharma, Lowe's Companies, P&G Sept 19 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Athira Pharma, Lowe's Companies and P&G on Thursday. HIGHLIGHTS * Athira Pharma Inc ATHA.O : Mizuho cuts to neutral from outperform * Five Below Inc FIVE.O : JP Morgan cuts to underweight from neutral * Lowe's Companies Inc LOW.N : TD Cowen raises target price to $265 from $240 * P&G PG.N : JP Morgan rai
A
A
C
D
M
N
T
A
C

India's pharma index climbs after bumper Fed rate cut

BUZZ-India's pharma index climbs after bumper Fed rate cut ** India's Nifty pharma index .NIPHARM climbs 0.5%, snapping three straight sessions of losses ** Rise after the U.S. Federal Reserve started its monetary easing cycle with a large 50-basis-point rate cut MKTS/GLOB ** Indian pharma firms have a sizeable exposure to U.S. markets and earn a significant share of their rev from the geography ** Eighteen of the 21 index constituents are trading in green; top gainers Abbott India ABOT.NS and A
A

Indian shares set to open higher

INDIA STOCKS-Indian shares set to open higher BENGALURU, Sept 10 (Reuters) - Indian shares are set to open higher on Tuesday, tracking a rebound in global stocks ahead of the key U.S. inflation data and the Federal Reserve's interest rate decision. The GIFT Nifty GIFc1 was at 25,035 points, as of 08:06 a.m. IST, indicating the NSE Nifty 50 .NSEI will open above its previous close of 24,936.4. The benchmark Nifty 50 rose for the first time in four sessions on Monday, led by gains in consumer stoc
A
A

FDA Says Abbott Diabetes Care Inc Issues Recall For Certain Freestyle Libre 3 Sensors Due To Risk For Inaccurate High Glucose Readings

BRIEF-FDA Says Abbott Diabetes Care Inc Issues Recall For Certain Freestyle Libre 3 Sensors Due To Risk For Inaccurate High Glucose Readings Sept 5 (Reuters) - FDA: FDA: ABBOTT DIABETES CARE INC ISSUES RECALL FOR CERTAIN FREESTYLE LIBRE 3 SENSORS DUE TO RISK FOR INACCURATE HIGH GLUCOSE READINGS Further company coverage: ABT.N
A



Condiciones

Activos populares

Descargo de responsabilidades: Cada una de las entidades de XM Group proporciona un servicio de solo ejecución y acceso a nuestra plataforma de trading online, permitiendo a una persona ver o usar el contenido disponible en o a través del sitio web, sin intención de cambiarlo ni ampliarlo. Dicho acceso y uso están sujetos en todo momento a: (i) Términos y Condiciones; (ii) Advertencias de riesgo; y (iii) Descargo completo de responsabilidades. Por lo tanto, dicho contenido se proporciona exclusivamente como información general. En particular, por favor tenga en cuenta que, los contenidos de nuestra plataforma de trading online no son ni solicitud ni una oferta para entrar a realizar transacciones en los mercados financieros. Operar en cualquier mercado financiero implica un nivel de riesgo significativo para su capital.

Todo el material publicado en nuestra plataforma de trading online tiene únicamente fines educativos/informativos y no contiene –y no debe considerarse que contenga– asesoramiento ni recomendaciones financieras, tributarias o de inversión, ni un registro de nuestros precios de trading, ni una oferta ni solicitud de transacción con instrumentos financieros ni promociones financieras no solicitadas.

Cualquier contenido de terceros, así como el contenido preparado por XM, como por ejemplo opiniones, noticias, investigaciones, análisis, precios, otras informaciones o enlaces a sitios de terceros que figuran en este sitio web se proporcionan “tal cual”, como comentarios generales del mercado y no constituyen un asesoramiento en materia de inversión. En la medida en que cualquier contenido se interprete como investigación de inversión, usted debe tener en cuenta y aceptar que dicho contenido no fue concebido ni elaborado de acuerdo con los requisitos legales diseñados para promover la independencia en materia de investigación de inversiones y, por tanto, se considera como una comunicación comercial en virtud de las leyes y regulaciones pertinentes. Por favor, asegúrese de haber leído y comprendido nuestro Aviso sobre investigación de inversión no independiente y advertencia de riesgo en relación con la información anterior, al que se puede acceder aquí.

Advertencia de riesgo: Su capital está en riesgo. Los productos apalancados pueden no ser adecuados para todos. Por favor, tenga en cuenta nuestra Declaración de riesgos.